Silence Therapeutics PLC (NAS:SLN)
$ 22.33 1.19 (5.63%) Market Cap: 1.04 Bil Enterprise Value: 973.87 Mil PE Ratio: 0 PB Ratio: 41.35 GF Score: 43/100

Silence Therapeutics PLC at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 09:10PM GMT
Release Date Price: $24.78
Justin Hayward Burns
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. Welcome to the third and final day of the Barclays Global Healthcare Conference. My name is Justin Burns. I'm on the U.S. biopharmaceutical's team here at Barclays. And it's my pleasure to introduce Mark Rothera, the President and CEO of Silence Therapeutics.

Mark Andrew Rothera
Silence Therapeutics plc - President, CEO & Director

So Justin, thank you very much for the introduction and for the invitation, and I'm going to just put up some slides. And just to begin to say that Silence is a precision medicine company, and its technology is based on RNAi or siRNA as it's also known. And it's something that is incredibly embedded within this company, and I look forward to telling you a little bit about that and the outlook for the organization.

Next slide. So during the course of today's presentation, I'll make forward-looking statements. Next slide, please. So whilst not everyone knows Silence Therapeutics, it is a company that's been around for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot